Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940518 | 0.93 | MKNK1 (0.48) | KDM4ERXFP1MKNK1LIMK1EGFR | |
| SCHEMBL937346 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HTTLMNAGAASMN1; SMN2 | |
| SCHEMBL17307739 | 0.84 | P2RX3 (0.47) | KDM4ERXFP1MKNK1LIMK1EGFR | |
| SCHEMBL940524 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HTTLMNAGAASMN1; SMN2 | |
| SCHEMBL939632 | 0.83 | MKNK1 (0.62) | MKNK1 | |
| SCHEMBL17307692 | 0.83 | P2RX3 (0.48) | KDM4ERXFP1MKNK1LIMK1EGFR | |
| SCHEMBL17296473 | 0.82 | MKNK1 (0.48) | KDM4ERXFP1MKNK1LIMK1EGFR | |
| SCHEMBL17296435 | 0.79 | P2RX3 (0.49) | MKNK1LIMK1EGFRGPR55 | |
| SCHEMBL17307632 | 0.79 | EGFR (0.48) | KDM4ERXFP1MKNK1EGFR | |
| SCHEMBL17296440 | 0.79 | P2RX3 (0.49) | KDM4ERXFP1MKNK1LIMK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980309-A | Tricyclic fused pyrimidine compounds useful as HER2 inhibitors | 百时美施贵宝公司 | 2024-05-03 | — | — | CN | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2212332-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | ALDH1A1 514/4885HTT 257/4885LMNA 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.